| Full Name | James Bales |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 27 Years |
| Location | 485 N Ks Hwy 2, Anthony, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902454150 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 11-02574 (Kansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital District No. 6 Of Harper County Kansas | 3779571906 | 7 |
News Archive
Researchers have designed a wireless electronic monitoring device so thin it can be applied to the skin like a temporary tattoo. It could one day be used to monitor heart, brain and muscle activity of patients without their even noticing.
Preventable adverse events in hospitals occur 3 times more often among patients with communication problems, such as deafness, blindness, psychiatric disorders and multiple health issues or comorbidities, found researchers in this study of nearly 2,400 patient records from 20 hospitals in Quebec.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Pressure measurements enable a newly developed fall detector to "observe" falls that current sensors do not register, thus improving safety for older people who live at home.
› Verified 1 days ago
| Provider Name | Hospital District No. 6 Of Harper County Kansas |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1467427674 PECOS PAC ID: 3779571906 Enrollment ID: O20040505000589 |
News Archive
Researchers have designed a wireless electronic monitoring device so thin it can be applied to the skin like a temporary tattoo. It could one day be used to monitor heart, brain and muscle activity of patients without their even noticing.
Preventable adverse events in hospitals occur 3 times more often among patients with communication problems, such as deafness, blindness, psychiatric disorders and multiple health issues or comorbidities, found researchers in this study of nearly 2,400 patient records from 20 hospitals in Quebec.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Pressure measurements enable a newly developed fall detector to "observe" falls that current sensors do not register, thus improving safety for older people who live at home.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Bales, 485 N Ks Hwy 2, Anthony, KS 67003-2526 Ph: (620) 914-1200 | James Bales, 485 N Ks Hwy 2, Anthony, KS 67003-2526 Ph: (620) 914-1200 |
News Archive
Researchers have designed a wireless electronic monitoring device so thin it can be applied to the skin like a temporary tattoo. It could one day be used to monitor heart, brain and muscle activity of patients without their even noticing.
Preventable adverse events in hospitals occur 3 times more often among patients with communication problems, such as deafness, blindness, psychiatric disorders and multiple health issues or comorbidities, found researchers in this study of nearly 2,400 patient records from 20 hospitals in Quebec.
RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Pressure measurements enable a newly developed fall detector to "observe" falls that current sensors do not register, thus improving safety for older people who live at home.
› Verified 1 days ago